Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year, » Read more about: Massive Upside In Big Money Pharma Favorite? »
Read More
Best Trader Ever Says AI Will…
Stanley Druckenmiller is arguably the best trader in the world not because of the 30% returns he posted annualized on average over 30 years but because during that time frame he never had a losing year.
It would be nice to invest alongside him but those days are gone, because he now manages a Family Office only,
» Read more about: Best Trader Ever Says AI Will… »
Read More
Is This Space Stock Set For Blast Off?
It’s not every day of the week we cover stocks trading under $5 per share, which are technically considered penny stocks. It’s rarer still to discuss those trading under $2 per share, but one space stock now is just too interesting to gloss past.
Before proceeding further, we must first note that this stock has been nothing short of a train wreck for shareholders since first going public via a SPAC sponsored by dMY Technology Group.
» Read more about: Is This Space Stock Set For Blast Off? »
Read More
Why This Buffett Stock Is a Forever Buy
Among Warren Buffett’s favorite investments is Coca-Cola, a Dividend King that has raised its dividend annually for a remarkable 62 consecutive years. This track record puts Coca-Cola in the elite club of dividend-paying stocks that have increased their dividends annually for at least 50 years.
Such consistent dividend hikes not only help investors to combat inflation but also substantially compound their returns.
» Read more about: Why This Buffett Stock Is a Forever Buy »
Read More
1 Cloud SaaS Healthcare Stock to Buy on the Dip?
It might surprise many that Veeva Systems Inc. (NYSE:VEEV), best known for its cloud-based software solutions tailored to the life sciences industry, has maintained a core principle of putting customer success and product excellence ahead of short-term gains.
In a market crowded with SaaS companies seeking to serve a wide variety of enterprises,
» Read more about: 1 Cloud SaaS Healthcare Stock to Buy on the Dip? »
Read MoreThe Ivy
1 Cash Cow with Massive Upside
CVS Health (NYSE:CVS) share price declined by over 23% over the past twelve months. Hurting shareholders was the recent leadership transition from CEO Karen Lynch to David Joyner, a shift that brought uncertainty to the company’s direction as investors questioned the company’s stability while facing ongoing challenges.
» Read more about: 1 Cash Cow with Massive Upside »
Read MoreThe Spotlight
Will Ford’s EV Gamble Pay Off?
As we race towards the end of 2024, a full 17 million electric vehicles are projected to be sold, which if realized will translate to a whopping 1 in 5 of all car sales.
With demand for EV’s as strong as ever and competition from Tesla and China’s BYD stiffening, what does the future hold for Ford and its EV strategy?
» Read more about: Will Ford’s EV Gamble Pay Off? »
Read MoreThe Daily
5 Highest-Yielding Dividend Champions Are Incredible April Buys
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
» Read more about: 5 Highest-Yielding Dividend Champions Are Incredible April Buys »